TIRZEPATIDE, A DUAL GIP AND GLP-1 RECEPTOR AGONIST, INCREASES INSULIN SENSITIVITY AND IMPROVES PANCREATIC BETA-CELL FUNCTION IN TYPE 2 DIABETES

被引：0
|
作者：
Pirro, V. [1 ]
Nikooienejad, A. [1 ]
Lin, Y. [1 ]
Willency, J. [1 ]
Wilson, J. [1 ]
Duffin, K. [1 ]
Robins, D. [1 ]
Milicevic, Z. [1 ]
Haupt, A. [1 ]
Thomas, M. [1 ]
机构：
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2021年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P232 / #49
引用
收藏
页码：A165 / A165
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of tirzepatide, a dual GIP/GLP-1 receptor agonist, compared to insulin degludec in patients with type 2 diabetes (SURPASS-3)
    Ludvik, B.
    Giorgino, F.
    Jodar, E.
    Frias, J. P.
    Lando, L. Fernandez
    Brown, K.
    Bray, R.
    Rodriguez, A.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 245 - 245
  • [22] THE DUAL GIP AND GLP-1 RECEPTOR AGONIST TIRZEPATIDE IMPROVES BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES (T2D)
    Wilson, J.
    Nikooienejad, A.
    Lin, Y.
    Robins, D.
    Roell, W.
    Riesmeyer, J.
    Haupt, A.
    Duffin, K.
    Ruotolo, G.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : A164 - A165
  • [23] Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Urva, Shweta
    Quinlan, Tonya
    Landry, John
    Martin, Jennifer
    Loghin, Corina
    CLINICAL PHARMACOKINETICS, 2021, 60 (08) : 1049 - 1059
  • [24] Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Urva, Shweta
    Quinlan, Tonya
    Landry, John
    Ma, Xiaosu
    Martin, Jennifer A.
    Benson, Charles T.
    CLINICAL PHARMACOKINETICS, 2022, 61 (07) : 1057 - 1067
  • [25] Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Shweta Urva
    Tonya Quinlan
    John Landry
    Jennifer Martin
    Corina Loghin
    Clinical Pharmacokinetics, 2021, 60 : 1049 - 1059
  • [26] Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Shweta Urva
    Tonya Quinlan
    John Landry
    Xiaosu Ma
    Jennifer A. Martin
    Charles T. Benson
    Clinical Pharmacokinetics, 2022, 61 : 1057 - 1067
  • [27] Effect of tirzepatide, a dual GIP and GLP-1 receptor agonist, on glycaemic control and body weight in Japanese patients with type 2 diabetes
    Benson, C. T.
    Ohwaki, K.
    Furihata, K.
    Mimura, H.
    Oura, T.
    Imaoka, T.
    DIABETOLOGIA, 2019, 62 : S353 - S353
  • [28] Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes
    Nowak, Mariusz
    Nowak, Wojciech
    Grzeszczak, Wladyslaw
    ENDOKRYNOLOGIA POLSKA, 2022, 73 (04) : 745 - 755
  • [29] GIP and GLP-1 receptor agonism in the therapy of type 2 diabetes with a focus on tirzepatide
    Nauck, Michael A.
    Blueher, Matthias
    Meyhoefer, Sebastian M.
    Heitmann, Elke
    Goergens, Sven W.
    DIABETOLOGIE UND STOFFWECHSEL, 2023, 18 (06) : 475 - 487
  • [30] Tirzepatide, a dual GIP/GLP-1 receptor agonist, is effective and safe when added to basal insulin for treatment of type 2 diabetes (SURPASS-5)
    Dahl, D.
    Onishi, Y.
    Norwood, P.
    Huh, R.
    Patel, H.
    Rodriguez, A.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 13 - 14
12345